| Title |
The experience of canakinumab in renal amyloidosis secondary to Familial Mediterranean fever
|
|---|---|
| Published in |
Molecular and Cellular Pediatrics, August 2016
|
| DOI | 10.1186/s40348-016-0058-2 |
| Pubmed ID | |
| Authors |
Betul Sozeri, Nesrin Gulez, Malik Ergin, Erkin Serdaroglu |
| Abstract |
Familial Mediterranean fever (FMF) is an autosomal recessive disease characterized by self-limited recurrent attacks of fever and serositis. Patients may develop renal amyloidosis. Colchicine prevents attacks and renal amyloidosis. Five to 10 % of the patients with FMF are resistant or intolerant to colchicine. Herein, we reported our experience with clinical-laboratory features and treatment responses of a pediatric FMF patient with amyloidosis treated with canakinumab. We observed a significant decrease in proteinuria and increase growth in the patient. The most serious complication of FMF is the development of AA type amyloidosis which is characterized by proteinuria. Colchicine is the prototype drug that decreases production of amyloidogenic precursor protein. Occasionally, colchicine inadequate patient is observed, as in our case. Canakinumab is a human anti-IL-1β monoclonal antibody. Previously, canakinumab efficacy were shown in a limited number of studies. Our data, though limited to only one patient, emphasize that therapeutic intervention with canakinumab seems to be improve kidney function in colchicine-resistant FMF with renal amyloidosis. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 22 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 22 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Other | 3 | 14% |
| Student > Doctoral Student | 3 | 14% |
| Student > Bachelor | 3 | 14% |
| Researcher | 3 | 14% |
| Professor > Associate Professor | 2 | 9% |
| Other | 4 | 18% |
| Unknown | 4 | 18% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 8 | 36% |
| Pharmacology, Toxicology and Pharmaceutical Science | 3 | 14% |
| Biochemistry, Genetics and Molecular Biology | 2 | 9% |
| Agricultural and Biological Sciences | 1 | 5% |
| Veterinary Science and Veterinary Medicine | 1 | 5% |
| Other | 2 | 9% |
| Unknown | 5 | 23% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 04 September 2016.
All research outputs
#15,383,207
of 22,886,568 outputs
Outputs from Molecular and Cellular Pediatrics
#50
of 98 outputs
Outputs of similar age
#219,390
of 344,209 outputs
Outputs of similar age from Molecular and Cellular Pediatrics
#3
of 3 outputs
Altmetric has tracked 22,886,568 research outputs across all sources so far. This one is in the 22nd percentile – i.e., 22% of other outputs scored the same or lower than it.
So far Altmetric has tracked 98 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.0. This one is in the 38th percentile – i.e., 38% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 344,209 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 27th percentile – i.e., 27% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 3 others from the same source and published within six weeks on either side of this one.